Cogent Biosciences Announces Part 1b Data From SUMMIT Trial Evaluating Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis; 51% Week 12 Mean Change In Total Symptom Score, Including 70% Of Patients Achieving ≥50% Reduction In TSS At Week 12
Portfolio Pulse from Benzinga Newsdesk
Cogent Biosciences, Inc. (NASDAQ:COGT) reported positive data from Part 1b of the SUMMIT trial for bezuclastinib in NonAdvSM patients, showing significant symptom reduction and quality-of-life improvements. The trial, presented at the AAAAI meeting, demonstrated a 51% mean change in Total Symptom Score at week 12, with 70% of patients achieving a ≥50% reduction. The safety profile was comparable to placebo, with no severe adverse events. SUMMIT Part 2 has been initiated globally. Cogent plans an investor webcast to discuss these findings.
February 22, 2024 | 7:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cogent Biosciences reported positive outcomes from the SUMMIT trial for bezuclastinib, indicating significant symptom and quality-of-life improvements in NonAdvSM patients. The trial's success and the initiation of Part 2 could positively influence investor sentiment.
The positive trial results for bezuclastinib in treating NonAdvSM, a significant unmet medical need, along with the successful initiation of Part 2 of the trial, are likely to be viewed positively by investors. The safety profile and efficacy data suggest a strong potential for bezuclastinib to become a leading treatment option, which could drive COGT's stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100